



# STATE OF TENNESSEE

2020 Episodes of Care Results

# Results of Episodes of Care Program

CY 2015	CY 2016	CY 2017	CY 2018	CY 2019
<p><i>Estimated Savings*:</i>  <b>\$10.8 million</b></p> <ul style="list-style-type: none"> <li>Providers and hospitals reduced costs while maintaining quality of care</li> <li>Gain sharing payments to providers exceeded risk sharing payments by <b>\$280,000</b></li> </ul>	<p><i>Estimated Savings*:</i>  <b>\$14.5 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> for perinatal, total joint replacement, and COPD, and were mostly maintained for the remaining episodes</li> <li>Gain sharing payments to providers exceeded risk sharing payments by <b>\$395,000</b></li> </ul>	<p><i>Estimated Savings*:</i>  <b>\$28.6 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes</li> <li>Gain sharing payments to providers exceeded risk sharing payments by <b>\$206,900</b></li> </ul>	<p><i>Estimated Savings*:</i>  <b>\$38.3 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes</li> <li>Gain sharing payments to providers exceeded risk sharing payments by <b>\$686,000</b></li> </ul>	<p><i>Estimated Savings*:</i>  <b>\$45.2 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes</li> <li>Gain sharing payments totaled <b>\$1.9 million</b></li> <li>Due to COVID-19, all risk sharing payments have been waived for the 2019 performance period</li> </ul>
Includes the 3 episodes in performance in CY 2015	Includes the 8 episodes in performance in CY 2016	Includes the 19 episodes in performance in CY 2017	Includes the 27 episodes in performance in CY 2018	Includes the 45 episodes in performance in CY 2019

\*Compared to 3% projected medical cost trend

# COVID-19 and 2020 Episodes of Care Results

**Due to the ongoing COVID-19 pandemic, estimated savings will not be calculated for the Calendar Year (CY) 2020 performance period.**

The state recognizes that COVID-19 continues to be an unprecedented health and economic crisis for the provider community. In order to continue to support providers during this difficult time, the three TennCare Managed Care Organizations (MCOs) waived all episodes of care risk sharing payments for the 2020 performance period. Providers who have gain sharing payments in their final 2020 performance reports will receive those payments as planned, with no changes. For 2020, gain sharing payments totaled **\$1.1 million**.



# QUALITY PERFORMANCE

# Episode Gain Sharing Quality Metrics – Wave 1

Wave 1 Episodes*	CY 2014	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	Target Performance
<b>Perinatal (19,281 valid episodes)</b>								
1. HIV Screening ( $\geq 90\%$ )	90.2%	88.3%	87.7%	89.1%	92.8%	94.6%	91.5%	<i>Higher is better</i>
2. Group B Streptococcus Screening ( $\geq 90\%$ )	87.8%	85.9%	94.0%	95.5%	95.2%	96.7%	92.7%	<i>Higher is better</i>
3. C-Section Rate ( $\leq 38\%$ )	30.5%	31.6%	30.6%	31.2%	30.8%	29.9%	29.6%	<i>Lower is better</i>
<b>Acute Asthma Exacerbation (6,258 valid episodes)</b>								
1. Follow-up Visit with Physician ( $\geq 30\%$ )	N/A**	N/A**	29.6%	30.3%	32.4%	30.8%	27.4%	<i>Higher is better</i>
2. Patient on Appropriate Medication ( $\geq 60\%$ )	N/A**	N/A**	60.3%	65.4%	69.5%	66.8%	62.8%	<i>Higher is better</i>
<b>Total Joint Replacement (223 valid episodes)</b>								
1. Admission Within the Post-Trigger Window 1 ( $\geq 10\%$ )	N/A***	N/A***	N/A***	N/A***	N/A***	2.0%	3.1%	<i>Lower is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

\*\*There was a coding change to these quality metrics so there is no direct comparison

\*\*\*There was not a quality metric tied to gain sharing for this episode until the 2020 performance period.



# Episode Gain Sharing Quality Metrics – Wave 2

Wave 2 Episodes*	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	Target Performance
<b>Cholecystectomy (1,163 valid episodes)</b>							
1. Hospitalization in Post-Trigger Window ( $\leq 10\%$ )	0.8%	1.0%	0.9%	0.3%	0.2%	0.3%	<i>Lower is better</i>
<b>COPD (2,221 valid episodes)</b>							
1. Follow-up Care Within Post-Trigger Window ( $\geq 45\%$ )	45.1%	46.7%	47.4%	46.7%	48.1%	44.6%	<i>Higher is better</i>
<b>Acute PCI (171 valid episodes)</b>							
1. Hospitalization in Post-Trigger Window ( $\leq 10\%$ )	1.0%	0.7%	0.7%	1.1%	0.9%	0.0%	<i>Lower is better</i>
<b>Non-acute PCI (28 valid episodes)</b>							
1. Hospitalization in Post-Trigger Window ( $\leq 10\%$ )	0.0%	1.6%	0.0%	0.0%	0.0%	0.0%	<i>Lower is better</i>

**Note:** There are no quality metrics tied to gain sharing for the colonoscopy episode

\*Valid episodes in 2020 performance period across all three MCOs



# Episode Gain Sharing Quality Metrics – Wave 3

Wave 3 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	Target Performance
<b>GI Hemorrhage (705 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 45%)	49.0%	51.9%	50.1%	50.0%	47.7%	<i>Higher is better</i>
<b>Pneumonia (2,041 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	N/A	N/A**	30.4%	30.4%	29.3%	<i>Higher is better</i>
<b>UTI-Inpatient (778 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 40%)	46.0%	43.5%	42.4%	41.1%	43.8%	<i>Higher is better</i>
<b>UTI-Outpatient (23,999 valid episodes)</b>						
1. Admission Within the Trigger Window for ED Triggered Episodes (≤ 5%)****	5.6%	6.1%	7.0%	6.3%	7.3%	<i>Lower is better</i>
2. Admission Within the Trigger Window for Non-ED Triggered Episodes (≤ 5%)****	0.8%	1.0%	1.0%	1.0%	0.9%	<i>Lower is better</i>
<b>Respiratory Infection (201,644 valid episodes)</b>						
1. ED Visit Within the Post-Trigger Window (≤ 10%)	N/A****	N/A****	N/A****	2.6%	2.2%	<i>Lower is better</i>
<b>EGD (5,209 valid episodes)</b>						
1. ED Visit Within the Post-Trigger Window (≤ 10%)	N/A****	N/A****	N/A****	4.0%	4.0%	<i>Lower is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

\*\*There was a coding change to these quality metrics so there is no direct comparison

\*\*\*This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes

\*\*\*\*There was not a quality metric tied to gain sharing for this episode until the 2020 performance period



# Episode Gain Sharing Quality Metrics – Wave 4

Wave 4 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	Target Performance
<b>Bariatric Surgery (602 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	35.6%	37.4%	43.3%	43.0%	42.2%	Higher is better
<b>CHF Acute Exacerbation (1,777 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 60%)	56.2%	57.2%	57.0%	56.0%	54.6%	Higher is better
<b>ODD (1,533 valid episodes)</b>						
1. Minimum Care Requirement (≥ 30%)	26.7%	35.8%	31.9%	30.7%	34.4%	Higher is better
<b>CABG (60 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	71.4%	70.0%	78.5%	81.6%	88.3%	Higher is better
<b>Valve Repair and Replacement (11 valid episodes)</b>						
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	78.5%	77.7%	76.7%	100.0%	63.6%	Higher is better
<b>ADHD (26,564 valid episodes)</b>						
1. Minimum Care Requirement (≥ 70%)	N/A**	78.5%	78.8%	77.6%	74.0%	Higher is better
2. Long-acting Stimulants for Members Aged 6 to 11 Years (≥ 80%)***	N/A**	83.1%	82.9%	83.6%	80.7%	Higher is better
3. Long-acting Stimulants for Members Aged 12 to 20 Years (≥ 80%)***	N/A**	83.0%	83.1%	83.9%	82.7%	Higher is better
4. Utilization of Therapy for Members Aged 4 and 5 Years (1 visit)***	N/A**	1.42	1.71	1.60	1.24	Higher is better

\*Valid episodes in 2020 performance period across all three MCOs

\*\*The preview period for the ADHD episode was 2017. The initial performance period for the ADHD episode was 2018

\*\*\* This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes





# Episode Gain Sharing Quality Metrics – Wave 5

Wave 5 Episodes*	CY 2017	CY 2018	CY 2019	CY 2020	Target Performance
<b>Breast Biopsy (461 valid episodes)*</b>					
1. Appropriate Diagnostic Workup Rate ( $\geq 90\%$ )	82.8%	80.8%	85.1%	83.5%	<i>Higher is better</i>
2. Core Needle Biopsy Rate ( $\geq 85\%$ )**	77.5%	82.2%	92.0%	92.0%	<i>Higher is better</i>
<b>Tonsillectomy (3,944 valid episodes)</b>					
1. Bleeding Up to Two Days Following the Procedure ( $\leq 5\%$ )	0.7%	0.5%	0.7%	0.7%	<i>Lower is better</i>
<b>Otitis Media (74,295 valid episodes)</b>					
1. Otitis Media with Effusion (OME) Episodes without Antibiotics Filled ( $\geq 25\%$ )**	27.7%	26.2%	31.6%	35.2%	<i>Higher is better</i>
2. Non-OME Episodes with Amoxicillin ( $\geq 60\%$ )**	64.3%	66.9%	65.1%	63.7%	<i>Higher is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

\*\* This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



# Episode Gain Sharing Quality Metrics – Wave 6

Wave 6 Episodes*	CY 2017	CY 2018	CY 2019	CY 2020	Target Performance
<b>Skin and Soft Tissue Infection (31,083 valid episodes)</b>					
1. Bacterial Cultures when Incision and Drainage Performed ( $\geq 50\%$ )**	42.4%	42.5%	40.7%	42.4%	Higher is better
2. SSTI Episodes with a First Line Antibiotic ( $\geq 85\%$ )**	97.7%	97.8%	98.0%	97.6%	Higher is better
<b>HIV (1,254 valid episodes)</b>					
1. Periodic anti-retroviral therapy (ART) refill ( $\geq 85\%$ )	71.6%	73.1%	73.8%	75.8%	Higher is better
<b>Diabetes Acute Exacerbation (638 valid episodes)</b>					
1. Follow-up care in the first 14 days of the post-trigger window ( $\geq 30\%$ )	25.4%	30.6%	30.3%	27.9%	Higher is better
<b>Pancreatitis (401 valid episodes)</b>					
1. Follow-up care in the first 14 days of the post-trigger window ( $\geq 35\%$ )	31.9%	35.8%	30.7%	32.9%	Higher is better

\*Valid episodes in 2020 performance period across all three MCOs

\*\* This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



# Episode Gain Sharing Quality Metrics – Wave 7

Wave 7 Episodes*	CY 2018	CY 2019	CY 2020	Target Performance
<b>Spinal Fusion (218 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 8.0$ )	0.04	4.26	2.17	<i>Lower is better</i>
<b>Spinal Decompression (104 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	1.38	5.71	1.40	<i>Lower is better</i>
<b>Femur/Pelvic Fracture (128 valid episodes)</b>				
1. Related follow-up care ( $\geq 30\%$ )	6.8%	9.6%	7.0%	<i>Higher is better</i>
2. Difference in Average MED/Day ( $\leq 8.0$ )	2.00	0.97	10.03**	<i>Lower is better</i>
<b>Knee Arthroscopy (746 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	-0.96	0.66	-0.47	<i>Lower is better</i>
<b>Non-operative Ankle Injury (10,464 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	0.02	0.38	0.87	<i>Lower is better</i>
<b>Non-operative Wrist Injury (5,986 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	0.11	0.47	0.19	<i>Lower is better</i>
<b>Non-operative Shoulder Injury (5,384 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	0.45	0.78	1.37	<i>Lower is better</i>
<b>Non-operative Knee Injury (5,508 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	0.73	0.05	1.01	<i>Lower is better</i>
<b>Back/Neck Pain (36,825 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	1.98	2.28	4.58	<i>Lower is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

\*\*This quality metric is based on a formula related to opioid prescriptions. The increase for these metrics was driven by a few episode outliers that are being investigated and addressed by the Managed Care Organizations and aligned with TennCare's overall opioid strategy. For more information on TennCare's Opioid Strategy, please visit the following website - <https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>

# Episode Gain Sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2018	CY 2019	CY 2020	Target Performance
<b>Acute Seizure (4,547 valid episodes)</b>				
1. Brain MRI Utilization in Focal Epilepsy ( $\geq 10\%$ )**	18.0%	18.7%	18.3%	<i>Higher is better</i>
2. Prolonged EEG Monitoring Utilization in Newly Diagnosed Seizure ( $\geq 10\%$ )**	7.4%	5.7%	2.8%	<i>Higher is better</i>
<b>Syncope (4,559 valid episodes)</b>				
1. Carotid Ultrasound Imaging in Adults ( $\leq 10\%$ )**	5.8%	4.0%	3.7%	<i>Lower is better</i>
<b>Bronchiolitis (1,857 valid episodes)</b>				
1. Related Admission during the Post-Trigger Window ( $\leq 10\%$ )	1.1%	1.1%	0.8%	<i>Lower is better</i>
2. Utilization of Bronchodilators ( $\leq 30\%$ )	14.4%	16.9%	13.0%	<i>Lower is better</i>
3. Utilization of Steroids ( $\leq 50\%$ )	22.0%	22.4%	20.4%	<i>Lower is better</i>
<b>Pediatric Pneumonia (1,260 valid episodes)</b>				
1. Related Admission during the Post-Trigger Window ( $\leq 10\%$ )	1.3%	1.2%	0.6%	<i>Lower is better</i>
2. Utilization of Macrolides in Patients Under 6 Years Old ( $\leq 30\%$ )**	19.7%	20.7%	18.2%	<i>Lower is better</i>
3. Utilization of Narrow Spectrum Antibiotics ( $\geq 50\%$ )	52.0%	57.6%	56.7%	<i>Higher is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

\*\* This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



# Episode Gain Sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2018	CY 2019	CY 2020	Target Performance
<b>Colposcopy (2,657 valid episodes)</b>				
1. LEEP Utilization Under 26 Years Old With No Evidence of High-Grade Dysplasia ( $\leq 10\%$ )**	4.2%	4.2%	1.9%	<i>Lower is better</i>
2. LEEP Utilization with Low-grade Dysplasia ( $\leq 10\%$ )**	9.5%	7.0%	11.0%	<i>Lower is better</i>
<b>Hysterectomy (631 valid episodes)</b>				
1. Alternative Treatments ( $\geq 20\%$ )	31.0%	34.2%	43.7%	<i>Higher is better</i>
2. Related Follow-up Care ( $\geq 10\%$ )	19.2%	20.1%	22.2%	<i>Higher is better</i>
<b>GI Obstruction (149 valid episodes)</b>				
1. Related Follow-up Care ( $\geq 20\%$ )	33.0%	32.6%	35.6%	<i>Higher is better</i>
2. Difference in Average MED/Day ( $\leq 0.0$ )	4.13	3.31	3.53	<i>Lower is better</i>
<b>Appendectomy (867 valid episodes)</b>				
1. Abdominopelvic CT Scans in Children ( $\leq 50\%$ )**	42.4%	36.9%	39.2%	<i>Lower is better</i>
1. Difference in Average MED/Day ( $\leq 0.0$ )	-0.21	-0.09	1.55	<i>Lower is better</i>
<b>Hernia Repair (951 valid episodes)</b>				
1. Difference in Average MED/Day ( $\leq 0.0$ )	0.12	0.63	1.39	<i>Lower is better</i>
<b>Acute Gastroenteritis (14,173 valid episodes)</b>				
1. Abdominopelvic CT or MRI in Adults ( $\leq 40\%$ )**	N/A	41.1%	45.3%	<i>Lower is better</i>
2. Abdominopelvic CT or MRI in Children ( $\leq 40\%$ )**	N/A	4.7%	6.3%	<i>Lower is better</i>
3. Antibiotics Utilization ( $\leq 30\%$ )	N/A	21.9%	24.1%	<i>Lower is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

\*\* This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes

# Episode Gain Sharing Quality Metrics – Wave 9

Wave 9 Episodes*	CY 2019	CY 2020	Target Performance
<b>Cystourethroscopy (845 valid episodes)</b>			
1. Difference in Average MED/Day ( $\leq 0.0$ )	0.35	-0.22	<i>Lower is better</i>
2. Related ED Visit ( $\leq 10\%$ )	5.4%	5.6%	<i>Lower is better</i>
3. Repeat cystourethroscopy ( $\leq 5\%$ )	2.8%	2.6%	<i>Lower is better</i>
<b>Acute Kidney and Ureter Stones (1,680 valid episodes)</b>			
1. Difference in Average MED/Day ( $\leq 3.0$ )	2.49	3.16	<i>Lower is better</i>
2. Related ED Visit ( $\leq 15\%$ )	18.9%	16.0%	<i>Lower is better</i>

\*Valid episodes in 2020 performance period across all three MCOs

